CTCL Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about CTCL clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+8 more
Ossium Health, Inc.12 enrolled9 locationsNCT05589896
Recruiting

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Chronic Lymphocytic Leukemia (CLL)Hairy Cell Leukemia (HCL)Non-Hodgkins Lymphoma (NHL)+2 more
National Cancer Institute (NCI)1,263 enrolled1 locationNCT01087333
Recruiting
Phase 2

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

CTCL
Prescient Therapeutics, Ltd.115 enrolled15 locationsNCT06854653
Recruiting
Phase 2

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

Lymphoma, T-CellT-LGL LeukemiaNK-LGL Leukemia+7 more
Institute of Hematology & Blood Diseases Hospital, China48 enrolled2 locationsNCT06716658
Recruiting
Phase 3

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

Mycosis FungoidesCutaneous T Cell LymphomaCTCL+1 more
Soligenix80 enrolled17 locationsNCT06470451
Recruiting

SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

Chronic Spontaneous Urticaria (CSU)Hidradenitis Suppurativa (HS)Psoriasis (PsO)+2 more
Leiden University Medical Center840 enrolled8 locationsNCT07021495
Recruiting
Phase 1Phase 2

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

T-cell Non-Hodgkin LymphomaT-cell Lymphoma (PTCL and CTCL)
Beijing GoBroad Hospital36 enrolled3 locationsNCT07022964
Recruiting
Phase 1Phase 2

CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas

T-cell Non-Hodgkin LymphomaT-cell Lymphoma (PTCL and CTCL)
Beijing GoBroad Hospital36 enrolled4 locationsNCT06925464
Recruiting
Phase 1

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

Peripheral T Cell LymphomaCutaneous T Cell Lymphoma (CTCL)NHL (Non-Hodgkin Lymphoma)
Tianjin Medical University Cancer Institute and Hospital24 enrolled1 locationNCT06914037